Skylands Capital LLC Grows Holdings in Haemonetics Corporation (NYSE:HAE)

Skylands Capital LLC lifted its stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 105.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,775 shares of the medical instruments supplier's stock after purchasing an additional 28,600 shares during the quarter. Skylands Capital LLC owned 0.11% of Haemonetics worth $3,545,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics during the fourth quarter worth $25,000. Covestor Ltd boosted its stake in shares of Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. bought a new stake in shares of Haemonetics during the fourth quarter worth about $62,000. Parkside Financial Bank & Trust increased its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its position in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Down 0.1%

Shares of NYSE:HAE traded down $0.06 during midday trading on Wednesday, hitting $76.26. 489,218 shares of the company's stock were exchanged, compared to its average volume of 669,966. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. Haemonetics Corporation has a 12 month low of $55.30 and a 12 month high of $94.99. The company has a market cap of $3.66 billion, a PE ratio of 23.04, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. The stock has a 50 day moving average price of $68.51 and a 200-day moving average price of $68.08.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 EPS. On average, sell-side analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the topic of several analyst reports. JMP Securities reissued a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Baird R W raised Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Robert W. Baird assumed coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Needham & Company LLC reduced their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.80.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.